Vatsala Katiyar, MD
Hematology & Oncology · Louisville, KYNPI 1215450119
Payments from drug & device makers
Across 251 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$903
- Sanofi$583
- Seagen Inc.$452
- Rigel Pharmaceuticals, Inc.$345
- Incyte Corporation$332
- Regeneron Healthcare Solutions, Inc.$314
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,77593%
- Education$4557%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 42 | $903 |
| Sanofi | 12 | $583 |
| Seagen Inc. | 16 | $452 |
| Rigel Pharmaceuticals, Inc. | 7 | $345 |
| Incyte Corporation | 21 | $332 |
| Regeneron Healthcare Solutions, Inc. | 7 | $314 |
| Eisai Inc. | 9 | $274 |
| Daiichi Sankyo Inc. | 11 | $210 |
| E.r. Squibb & Sons, L.L.C. | 12 | $203 |
| Gilead(2 entities) | 10 | $200 |
| Pharmacyclics LLC, An Abbvie Company | 8 | $184 |
| AstraZeneca | 8 | $164 |
| EMD Serono, Inc. | 7 | $162 |
| Adaptive Biotechnologies Corporation | 3 | $154 |
| Beigene USA, Inc. | 6 | $145 |
| Bayer | 9 | $144 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Johnson & Johnson | 6 | $116 |
| Pfizer | 5 | $115 |
| Merck | 6 | $113 |
| ADC Therapeutics America, Inc. | 2 | $112 |
| Mirati Therapeutics, Inc. | 3 | $103 |
| AbbVie | 5 | $101 |
| Boehringer Ingelheim | 6 | $94 |
| Novartis | 4 | $91 |
| Ipsen Biopharmaceuticals, Inc | 3 | $62 |
| Sobi, Inc | 3 | $58 |
| Lilly USA, LLC | 4 | $57 |
| Bristol Myers Squibb | 1 | $50 |
| Coherus Oncology, Inc. | 2 | $48 |
| Dova Pharmaceuticals | 2 | $37 |
| Deciphera Pharmaceuticals Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $34 |
| Stemline Therapeutics Inc. | 1 | $29 |
| CTI Biopharma Corp. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $17 |
| Apellis Pharmaceuticals, Inc. | 1 | $16 |
| Immunomedics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,229 in reported general payments places this provider in the 40th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 20 | $353,333 |
| RevlimidLenalidomide | 12 | $232,550 |
| VerzenioAbemaciclib | 13 | $201,286 |
| XtandiEnzalutamide | 14 | $179,935 |
| FulphilaPegfilgrastim-Jmdb | 20 | $39,075 |
| EliquisApixaban | 40 | $27,250 |
| OrgovyxRelugolix | 11 | $26,091 |
| Imatinib Mesylate | 11 | $12,547 |
| Abiraterone Acetate | 26 | $11,155 |
| Acyclovir | 52 | $731 |
| Gabapentin | 15 | $609 |
| Anastrozole | 31 | $539 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 24 | $515 |
| Prochlorperazine Maleate | 41 | $435 |
| Dexamethasone | 49 | $352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $50 | $232,55012 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $57 | $201,40035 claims |
| PfizerEliquis | $115 | $27,25040 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $125 | $11,15526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 143 hematology & oncology providers in Kentucky.
Other hematology & oncology in Louisville
- Joseph MalyLouisville$7M
- Laila AgrawalLouisville$6.3M
- Jaspreet GrewalLouisville$4.2M
- Rebecca RedmanLouisville$2.1M
- Vivek SharmaLouisville$1.9M
- Rohit KumarLouisville$1.6M
- Jeffrey HargisLouisville$1.3M
- Goetz KloeckerLouisville$1.2M
- Elizabeth RileyLouisville$746K
- Adam LyeLouisville$706K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.